Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PYGB | P11216 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30029591 | 1.00 | GBA1 (0.49) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL31001202 | 1.00 | GBA1 (0.49) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL13281076 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL20897004 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL13281078 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL23906986 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL3832277 | 0.95 | GBA1 (0.56) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL10786697 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| SCHEMBL23787746 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 | |
| Hexane SCHEMBL28784867 | 0.94 | GBA1 (0.59) | GBA1KDM4ELMNACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533478-A | Therapeutic compositions and related methods | 3M创新有限公司 | 2021-03-19 | — | — | CN | claimed |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| CN-119490978-B | Modified starch-based surfactant and preparation method and application thereof | 佛山市益境环保科技有限公司温州分公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119490978-A | Modified starch-based surfactant and preparation method and application thereof | 佛山市益境环保科技有限公司温州分公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025000280-A1 | COMPOUND FOR PREVENTING OR TREATING CANINE BONE OR JOINT DISEASES, COMPOSITION, AND USE | 润佳（苏州）医药科技有限公司 | 2025-01-02 | — | — | WO | disclosed |
| US-12110532-B2 | In vitro glycosylation of proteins and enzymes | DESIGN- ZYME LLC (US) | 2024-10-08 | — | — | US | disclosed |
| CN-115215911-B | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-115594724-A | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-115215911-A | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-111971290-B | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-109929001-B | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210230661-A1 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | Design-Zyme LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-11021730-B2 | In vitro glycosylation of proteins and enzymes | Design-Zyme LLC | 2021-06-01 | — | — | US | disclosed |
| CN-112533478-A | Therapeutic compositions and related methods | 3M创新有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20190185900-A1 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | Design-Zyme LLC (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021730-B2 | In vitro glycosylation of proteins and enzymes | ALDH7A1, OGA, DAO | GBA1 2725/4885KDM4E 1484/4885LMNA 3085/4885 |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | GBA1 62/4885KDM4E 3651/4885LMNA 2743/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | GBA1 76/4885KDM4E 3639/4885LMNA 3002/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | GBA1 239/4885KDM4E 2916/4885LMNA 992/4885 |
| US-20210230661-A1 | IN VITRO GLYCOSYLATION OF PROTEINS AND ENZYMES | ALDH7A1, OGA, DAO | GBA1 2725/4885KDM4E 1484/4885LMNA 3085/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | GBA1 62/4885KDM4E 3651/4885LMNA 2743/4885 |
| US-12110532-B2 | In vitro glycosylation of proteins and enzymes | ALDH7A1, OGA, DAO | GBA1 2725/4885KDM4E 1484/4885LMNA 3085/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | GBA1 76/4885KDM4E 3639/4885LMNA 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.